Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safinamide (ME2125) add-on therapy in Parkinson's disease with wearing-off
jRCT2080223003Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of safinamide in Parkinson's disease (PD) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Long-term safety and tolerability of safinamide add-on therapy. Started Nov 2015; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080223003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223003.